Ravi Alvala Selected Research

Neoplasms (Cancer)

4/2024	Design and synthesis of novel coumarin-benzimidazole hybrids as human galectin-1 inhibitors.
1/2023	Coumarin and Piperazine Conjugates as Selective Inhibitors of the Tumor-associated Carbonic Anhydrase IX and XII Isoforms.
8/2021	An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016-present).
1/2021	Synthesis and biological evaluation of novel 4,7-disubstituted coumarins as selective tumor-associated carbonic anhydrase IX and XII inhibitors.
1/2020	Synthesis, 18F-radiolabeling and apoptosis inducing studies of novel 4, 7-disubstituted coumarins.
1/2020	Novel benzimidazole-triazole hybrids as apoptosis inducing agents in lung cancer: Design, synthesis, 18F-radiolabeling & galectin-1 inhibition studies.
1/2019	Synthesis and Biological Evaluation of Novel Heterocyclic Imines Linked Coumarin- Thiazole Hybrids as Anticancer Agents.
1/2019	Synthesis and biological evaluation of morpholines linked coumarin-triazole hybrids as anticancer agents.
1/2019	Human Galectin-1 and Its Inhibitors: Privileged Target for Cancer and HIV.
1/2012	Synthesis and in vitro antiproliferative activity of 2-methyl-3-(2-piperazin-1-yl-ethyl)-pyrido[1,2-a]pyrimidin-4-one derivatives against human cancer cell lines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ravi Alvala Research Topics

Disease

10	Neoplasms (Cancer) 04/2024 - 01/2012
2	Neoplasm Metastasis (Metastasis) 01/2019 - 01/2019
1	Fibrosis (Cirrhosis) 08/2021
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Immune System Diseases (Immune Disorders) 01/2019
1	Melanoma (Melanoma, Malignant) 01/2019
1	Osteosarcoma (Osteogenic Sarcoma) 01/2019
1	Diabetes Mellitus 04/2016
1	Chronic Disease (Chronic Diseases) 04/2016
1	Obesity 07/2013

Drug/Important Bio-Agent (IBA)

5	coumarinIBA 04/2024 - 01/2019
4	Galectin 1 (LGALS1)IBA 01/2020 - 01/2019
3	1-nitrohydroxyphenyl-N-benzoylalanine (GAL 1)IBA 04/2024 - 01/2019
3	Proteins (Proteins, Gene)FDA Link 08/2021 - 07/2013
2	benzimidazoleIBA 04/2024 - 01/2020
2	Carbonic Anhydrase IXIBA 01/2023 - 01/2021
2	Protein Isoforms (Isoforms)IBA 01/2023 - 01/2021
2	CoumarinsIBA 01/2021 - 01/2020
2	TriazolesIBA 01/2020 - 01/2019
2	LectinsIBA 01/2019 - 01/2019
1	CarbohydratesIBA 04/2024
1	PiperazineIBA 01/2023
1	Carbonic Anhydrases (Carbonic Anhydrase)IBA 01/2021
1	5,5',6,6'- tetrachloro- 1,1',3,3'- tetraethylbenzimidazolocarbocyanineIBA 01/2020
1	FITC-annexin A5IBA 01/2020
1	Matrix Metalloproteinases (MMPs)IBA 01/2020
1	DAPIIBA 01/2020
1	Fluorine-18IBA 01/2020
1	GalactosidesIBA 01/2019
1	IminesIBA 01/2019
1	MorpholinesIBA 01/2019
1	ThiazolesIBA 01/2019
1	Galectins (Galectin)IBA 01/2019
1	Insulin (Novolin)FDA Link 04/2016
1	Blood Glucose (Blood Sugar)IBA 04/2016
1	Sirtuin 1IBA 07/2013
1	ethyl acetateIBA 07/2013
1	Messenger RNA (mRNA)IBA 07/2013
1	thiazolyl blueIBA 01/2012

Therapy/Procedure

1	Therapeutics 04/2024